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Abstract
Background: Flavaglines are a family of natural products from the genus Aglaia that exhibit anti-cancer activity in vitro and in
vivo and inhibit translation initiation. They have been shown to modulate the activity of eIF4A, the DEAD-box RNA helicase
subunit of the eukaryotic initiation factor (eIF) 4F complex, a complex that stimulates ribosome recruitment during translation
initiation. One flavagline, silvestrol, is capable of modulating chemosensitivity in a mechanism-based mouse model.
Methodology/Principal Findings: Among a number of flavagline family members tested herein, we find that silvestrol is the
more potent translation inhibitor among these. We find that silvestrol impairs the ribosome recruitment step of translation
initiation by affecting the composition of the eukaryotic initiation factor (eIF) 4F complex. We show that silvestrol exhibits
significant anticancer activity in human breast and prostate cancer xenograft models, and that this is associated with
increased apoptosis, decreased proliferation, and inhibition of angiogenesis. We demonstrate that targeting translation by
silvestrol results in preferential inhibition of weakly initiating mRNAs.
Conclusions/Significance: Our results indicate that silvestrol is a potent anti-cancer compound in vivo that exerts its activity
by affecting survival pathways as well as angiogenesis. We propose that silvestrol mediates its effects by preferentially
inhibiting translation of malignancy-related mRNAs. Silvestrol appears to be well tolerated in animals.
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Introduction
Cyclopenta[b]benzofuran flavaglines are inhibitors of transla-
tion initiation isolated from Asian plants of the genus Aglaia of the
family Meliacae [1–4]. These compounds show in vitro activity
against tumor cell lines [1,2], promising activity in xenograft
cancer models [2,5,6] and appear to block G2/M cell cycle
progression [7]. We have previously shown that the flavagline
silvestrol can re-sensitize tumor cells to standard-of-care agents,
such as doxorubicin, in the Em-myc lymphoma model [4].
Silvestrol inhibits translation initiation by targeting the RNA
helicase, eukaryotic initiation factor (eIF) 4A, and prevents
ribosome loading onto mRNA templates [4].
Translation initiation is regulated by eIF4F at the level of the
ribosome recruitment step. eIF4F is composed of three subunits:
eIF4E, which binds to the cap structure present at the 59 end of
mRNAs; eIF4A, a DEAD-box RNA helicase implicated in
preparing a ribosome landing pad for 43S pre-initiation complexes
(40S ribosomal subunit and associated factors) by unwinding 59
mRNA structure; and eIF4G, a large scaffolding protein involved
in recruiting the 43S pre-initiation complex via its interaction with
40S-associated eIF3 [8]. eIF4A is an abundant translation factor
that exists in a free form (referred to herein as eIF4Af) and as a
subunit of the heterotrimeric eIF4F complex (eIF4Ac) [9,10]. The
helicase activity of eIF4Ac is ,20-fold more efficient than eIF4Af
and during initiation, eIF4Af likely cycles through the eIF4F
complex [11]. Silvestrol acts as a chemical inducer of dimerization
(CID) to force an engagement between eIF4Af and RNA, although
how this inhibits translation initiation is not known [4].
Levels of cellular eIF4F are regulated by the target of rapamycin,
mTOR [12,13]. The extent to which translation of specific mRNAs
is altered in response to changes in mTOR activity and eIF4F levels
varies substantially among different transcripts and is largely
dependent upon sequence elements within each mRNA, such as
the presence of discrete hairpin structures in the 59 untranslated
regions [14]. Many cellular mRNAs are characterized by relatively
short, unstructured 59 UTRs (e.g. b-actin, GAPDH) that require a
minimal amount of eIF4F for 43S pre-initiation complexes
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activity is limiting. By comparison, a select group of mRNAs is
extremely sensitive to, and dependent upon, eIF4F for translation.
These mRNAs typically harbor lengthy, G+C rich, highly-
structured 59 UTRs that encumber efficient RNA unwinding by
the eIF4F complex and subsequently prevent efficient ribosome
loading [14]. Hence, altering levels with flavaglines can exert
profound gene specific effects.
The deregulation of the PI3k/Akt/mTOR signaling axis in
human cancers, the finding that ectopic expression of eIF4E is
oncogenic [15,16], and the demonstration that targeted down-
regulation of eIF4E displays therapeutic benefit in xenograft
mouse models [17] suggest that the process of translation initiation
is a potential anti-cancer target. Herein, we report that silvestrol is
effective against two human xenograft models as a single agent.
We provide further insight into the mechanism of action of
silvestrol and show that it depletes the eIF4F complex of eIF4A
and this is associated with a preferential reduction in the
translation of mRNAs with structured 59untranslated regions.
Our results are consistent with the idea that silvestrol’s anticancer
activity is linked to its ability to preferentially block translation of
highly structured, malignancy-related mRNAs.
Results
Structure-activity relationships of flavaglines
We have previously characterized silvestrol as an inhibitor of
translation initiation in vitro and in vivo [4]. To determine how
extensive this property is among flavaglines, we tested members of
the cyclopenta[b]benzofurans, cyclopent[bc]benzopyrans, and
benzo[b]oxepines family for their potential to inhibit protein
synthesis. (Fig. 1 and Figs. S1 and S2). Among the compounds
tested were rocaglaol (Fig. 1A, compound #4) [18], that has been
shown to induce apoptosis and cell cycle arrest in LNCaP cells [7];
aglafolinformylester (compound #7) [19], which has been shown
to inhibit cap specific translation initiation (4) and silvestrol, which
can sensitize lymphomas to the cytotoxic action of doxorubicin (4).
In vitro translation reactions in extracts programmed with the
bicistronic mRNA, FF/HCV/Ren (Fig. S1A), revealed that
although compound #7 inhibited FF translation to the greatest
extent when compared to compounds 1–11 (Fig. 1B and Fig. S1B),
it was not as potent as silvestrol in vitro (Figs. 1C) or in vivo (Fig. 1D).
The closely related cyclopenta[bc]benzopyrans and benzo[b]ox-
epines flavagline-type compounds did not show significant activity
as inhibitors of translation (Fig. S2). We focused the remainder of
our studies on silvestrol since it displayed the most potent
inhibition of protein synthesis among the flavaglines that we have
identified to date.
Mechanism of Action of Silvestrol
We have previously demonstrated that silvestrol acts as a
chemical inducer of dimerization – promoting the interaction
between eIF4A and RNA [4]. We confirmed that silvestrol
increases the RNA binding properties of eIF4A using nitrocellulose
binding assays (Fig. 2A). In this assay,
32P-labeled RNA is retained
on nitrocellulose filters only when bound to proteins. Very little
RNA was retained by nitrocellulose when RNA was incubated
only in the presence of eIF4A (Fig. 2A, compare lane 2 to 1). In the
presence of pateamine, a CID that induces eIF4Af-RNA
interaction, a significant proportion of
32P-labeled RNA was
retained (Fig. 2A, compare lane 3 to 2) [20]. Addition of silvestrol
to the eIF4A-RNA binding reactions increased the retention of
32P-labeled RNA on nitrocellulose (compare lanes 5–8 to 2); an
event that was inhibited by hippuristanol (compare lane 9 to 7) – a
compound that binds to the C-terminal domain of eIF4A to inhibit
RNA binding [21]. These results indicate that silvestrol enhances
binding between eIF4Af and RNA.
We have previously shown that RNA binding of eIF4Ac is also
increased by silvestrol [4], and we now demonstrated that this was
a cap-dependent phenomenon (Fig. 2B). Crosslinking of eIF4E
and eIF4Ac from RSW to
32P-labeled mRNA cap structures was
inhibited by the presence of m
7GDP (Fig. 2B, compare lane 2 to
1). As previously documented [22], crosslinking of eIF4A, but not
eIF4E, was ATP-dependent (Fig 2B, compare lane 3 to 1). The
presence of silvestrol in the reaction stimulated the crosslinking of
eIF4Ac, but not eIF4E (compare lane 4 to 1). Crosslinking of
eIF4Ac in the presence of silvestrol was inhibited by m
7GDP and
required ATP (compare lanes 5–7 to 4).
One consequence of increased RNA binding of eIF4A in the
presence of silvestrol is that the eIF4F complex could become
depleted of eIF4Ac – thus reducing cap-dependent translation. We
therefore tested this possibility by purifying eIF4E from RSW
containing silvestrol (Fig. 2C; left panel) and from cell extracts that
had been prepared from MDA-MB-231 silvestrol-treated cells
(Fig. 2C; right panel) using m
7GTP-Sepharose affinity chroma-
tography. We then probed for the presence of eIF4E and co-
purifying eIF4A in m
7GTP eluates. In both cases, the levels of
eIF4Ac in the eIF4F complex were reduced (Figs. 2C).
To determine if components of the eIF4F complex (i.e.-eIF4G)
co-sequestered with eIF4A to RNA in the presence of silvestrol, we
performed pull-down assays with poly(rG)-agarose (Fig. 2D).
Increased eIF4A levels were retained on poly(rG)-agarose in the
presence of silvestrol and pateamine, however, this did not result in
a concomitant increase of eIF4G associating with poly(rG)-agarose
(Fig. 2D, compare lanes 2 and 3 to 1). [The small amount of
eIF4G binding to poly(rG)-agarose may be due to this proteins’
intrinsic RNA binding.]
Inhibition of translation by silvestrol leads to mRNA
discrimination
Silvestrol inhibited protein synthesis in MDA-MB-231 breast
and PC-3 prostate cancer cell lines with approximately the same
IC50 (,60 nM) following a 1 h exposure (Fig. 3A). We next
determined the extent to which 25 nM silvestrol would affect
protein synthesis rates in these cells. Translation rates were
monitored as a function of time-post-exposure to silvestrol by
labeling proteins with
35S-Met 15 min before harvest (Fig. 3B). A
biphasic response was noted with a precipitous drop occurring
over the first 8 h, followed by a slower reduction in translation
occurring from 8–72 h (Fig. 3B). The reduction in translation rates
was not a consequence of silvestrol-induced apoptosis since this
was only observed for MDA-MB-231 cells during the last 24 h of
the experiment (40% reduction in viability) (Fig. 3B). We noticed
that during the first 8 h following inhibition of protein synthesis by
silvestrol there was an ,2 fold decrease in
35S-met incorporation
into newly synthesized proteins for MDA-MB-231 (Fig. S3A:
between 0–4 h for MDA-MB-231 cells - compare lane 2 to 1) and
PC-3 (Fig. S3A: between 4–8 h for PC-3 cells: compare lane 3 to
2). By 24 h, we noted a reduction in the labeling of specific
proteins (Fig. S3A: denoted by open boxes). In contrast,
cycloheximide, an inhibitor of elongation, completely blocked
protein synthesis and reduced
35S-Met incorporation equivalently
in all proteins (data not shown).
These results indicate that treatment of cells with silvestrol
might lead to mRNA discrimination during translation. To
explore this, we generated reporter constructs in which a G-
quadruplex had been engineered into the 59 untranslated region of
the mRNA 6 nucleotides from the site of transcription initiation
eIF4A as Anti-Cancer Target
PLoS ONE | www.plosone.org 2 April 2009 | Volume 4 | Issue 4 | e5223Figure 1. Structure-activity relationship analysis of cyclopenta[b]benzofurans. A. Chemical structure of cyclopenta[b]benzofurans tested
in this study. B. Effect of cyclopenta[b]benzofurans on cap- and HCV-mediated translation initiation. Krebs-2 translation extracts were programmed
with FF/HCV/Ren mRNA and vehicle (MeOH) or 50 mM compound. The relative activity (compared to DMSO controls) from 3 independent translation
reactions is presented along with the standard error of the mean. [The partial inhibition of HCV-mediated translation has been previously
documented [4].] C. Dose–dependent inhibition of translation by flavaglines in RRL extracts. Extracts were programmed with FF/HCV/Ren mRNA and
firefly luciferase values determined and set relative to translations containing vehicle alone. The values obtained are the average of 2 experiments. D.
Dose–dependent inhibition of translation by flavaglines in MDA-MB-231 cells. Compounds were added to cells in culture at the indicated dose for
1h .
35S-methionine was added to cells 15 min before harvesting, after which TCA precipitable counts were determined and standardized against
total protein content. Values are set relative to those obtained from vehicle-treated cells. The values obtained are the average of 2 experiments.
doi:10.1371/journal.pone.0005223.g001
eIF4A as Anti-Cancer Target
PLoS ONE | www.plosone.org 3 April 2009 | Volume 4 | Issue 4 | e5223(Fig. S4A, G-Q(+6)/RL). The G-quadruplex was modeled on one
previously described to be present within the 59 UTR of NRAS
RNA and shown to mediate translational repression [23]. A
control construct, [CAA]10/RL, generated a reporter transcript
having a 59 UTR consisting of [CAA] tracts and harboring
minimal secondary structure with lowered eIF4F dependency [24].
As an internal control, we utilized a construct in which the HCV
IRES was driving expression of firefly luciferase, an element
known to recruit ribosomes in an eIF4F-independent manner [25].
Translation of G-Q(+6)/RL was more cap-dependent than
[CAA]10/RL in Krebs extracts, as judged by inhibition of
translation in the presence of m
7GDP (Fig. S4B). In addition, G-
Q(+6)/RL was more sensitive to reduced levels in eIF4A activity,
as determined by inhibition of translation in the presence of the
eIF4A inhibitor, hippuristanol [26]. In the presence of increasing
concentrations of silvestrol, translation of G-Q(+6)/RL was
inhibited to a greater degree than [CAA]10/RL mRNA (Fig.
S4C), being consistent with inhibition of translation by silvestrol
leading to mRNA discriminatory effects. This discriminatory effect
was also observed with another flavagline, compound #7 (Fig. 1A),
as well as on another set of reporter constructs in which the highly
structured HIV TAR element was placed upstream of the
chloramphenicol acetyl transferase (CAT) coding region (Fig.
S5A). The PLTAR element is inhibitory to translation initiation
and renders translation more sensitive to ionic concentrations [27]
(Fig. S5B; compare lane 7 to 4). PLTAR CAT mRNA translation
Figure 2. Silvestrol stimulates binding of eIF4A to mRNA. A. Silvestrol stimulates retention of eIF4AIf to mRNA. Radiolabeled CAT mRNA was
incubated with eIF4AIf and ATP in the presence of vehicle (DMSO), pateamine A (PatA), hippuristanol [45], or silvestrol (Sil) for 2 min after which time
the reactions were applied to nitrocellulose filters, washed and dried. The amount of radiolabeled mRNA retained on the filters was determined by
scintillation counting. The results are the average of three experiments with the standard error of the mean shown. B. Silvestrol stimulates cap-
dependent crosslinking of eIF4Ac. Chemical crosslinking of initiation factors to oxidized
32P-cap labeled CAT mRNA. The presence of 20 mM silvestrol
is indicated above the panel. The gel was dried and exposed to X-ray film (Kodak) at 280uC with an intensifying screen. C. Left Panel: Silvestrol
reduces the amount of eIF4Ac in the eIF4F complex. RSW was incubated with vehicle (0.5% DMSO) or 50 mM silvestrol for 1 h followed by m
7GTP-
affinity purification. Reactions were resolved on a 10% SDS-polyacrylamide gel followed by Western blot analysis. Right Panel: MDA-MB-231 cells
were treated with 25 nM silvestrol for 4 h, after which time, cell extracts were prepared and m
7GTP-affinity purifications performed. Reactions were
resolved on a 10% SDS-polyacrylamide gel followed by Western blot analysis. D. Krebs-2 extracts were treated with 50 mM of silvestrol for 10 min at
30uC. After incubation, poly (rG)-affinity purifications were performed. Eluates were resolved on a 10% SDS polyacrylamide gel and analyzed by
Western blotting.
doi:10.1371/journal.pone.0005223.g002
eIF4A as Anti-Cancer Target
PLoS ONE | www.plosone.org 4 April 2009 | Volume 4 | Issue 4 | e5223proved to be more sensitive to compound #7, than the CAT
reporter (Fig. S5B, compare lanes 8–11), indicating that the results
obtained with silvestrol are not compound- or reporter- specific
(Fig. S4).
We next asked whether exposure of cells to silvestrol would
affect the expression of malignancy-related proteins (Fig. 3C). We
chose to evaluate the oncogenes cyclin D1 and c-myc and the anti-
apoptotic proteins Bcl-2, survivin, and Mcl-1 since these have all
been reported to be eIF4E-dependent. Levels of cyclin D1, Bcl-2
and c-myc diminished within the first 8 h of exposing MDA-MB-
231 cells to silvestrol (Fig. 3C, compare lanes 1–3). Levels of
survivin and Mcl-1 decreased substantially after 48 h, whereas
tubulin and GAPDH expression was largely unaffected (Fig. 3C),
consistent with the notion that silvestrol selectively affects
production of growth-related proteins. Treatment of cells with
vehicle for 72 hrs did not change levels of any of these proteins
(Fig. 3C, compare lane 7 to 8). The levels of tubulin and GAPDH
seen at 48–72 hrs in silvestrol treated cells are also similar to levels
observed in untreated cells and thus cannot be attributed to
selective enhancement of their synthesis by silvestrol (Fig. 3C,
compare lanes 5 and 6 to 1). RT-PCR analysis of RNA isolated
from unbound and polysome-bound fractions from DMSO- and
silvestrol-treated MDA-MB-231 cells indicated that silvestrol leads
to a redistribution of mRNA from polysomes into unbound
fractions for these malignancy-related mRNAs (Fig. S3B). This is
consistent with silvestrol inhibiting translation initiation of these
transcripts.
We have previously shown that eIF2a is not phosphorylated in
response to exposure of cells to silvestrol [4], and wanted to assess
if inhibition of translation by silvestrol induced stress granule
formation, a common event associated with inhibition of
translation initiation. Arsenite, a known inducer of SGs caused
relocalization of eIF4A and eIF4E into SGs, as determined by co-
localization with the SG marker, G3BP (Fig. S6A, B). Exposure of
HeLa cells to silvestrol also induced colocalization of eIF4A, eIF4E
and G3BP into SGs (Fig. S6).
Figure 3. Silvestrol inhibits translation in vivo in MDA-MB-231 breast and PC-3 prostate cancer cells. A. Relative rate of
35S-Met
incorporation in MDA-MB-231 breast and PC-3 prostate cancer cells as a function of silvestrol concentration. Cells were exposed to the indicated
concentrations of silvestrol for 1 h in Met-free DMEM with 10% dialyzed FBS, during which the last 15 min,
35S-Met was added. Results are the
average of duplicates with the error of the mean shown. Values are standardized against total protein content and plotted relative to DMSO controls,
which were ,100,000 and 400,000 cpm/mg for MDA-MB-231 and PC-3 cells, respectively. B. Kinetics of protein inhibition and cell death following
exposure to silvestrol. Cells (60,000 per well in a 24-well plate) were exposed to 25 nM silvestrol for the indicated periods of time. One set of cells was
used to quantitate protein synthesis following
35S-Met-labeling, TCA precipitation, and scintillation counting. A parallel set of dishes (200,000 cells per
well in a 6-well plate) was used to measure the percentage of viable cells by Annexin V/P.I. staining followed by FACs analysis. These values were
normalized to those obtained in the presence of vehicle (1% DMSO), which was set to 100%. C. Reduction in expression of eIF4E-responsive gene
products in MDA-MB-231 cells exposed to silvestrol. Western blotting was used to evaluate protein levels from cell lysates harvested at the indicated
time points. The panels for survivin (lanes 7 and 8) were analyzed on the same gel, but not on adjacent lanes.
doi:10.1371/journal.pone.0005223.g003
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without cytotoxicity
The cap-dependent translation process is a target of silvestrol.
Injection of silvestrol for two consecutive days into mice caused a
reduction in liver protein synthesis, as assessed by polysome
analysis in liver tissue isolated 3 and 6 h after the second injection
(Fig. 4A). These results clearly indicate that silvestrol can inhibit
protein synthesis in vivo. We then administered silvestrol to non-
tumor bearing mice once a day for 8 consecutive days and assessed
if there was an effect on red blood cells, lymphocytes, or
monocyte/granulocyte counts from both bone marrow (BM) and
spleen (SP) of control and silvestrol-treated mice (Fig. 4B). Vehicle-
and silvestrol-treated animals displayed similar blood cell profiles
(Fig. 4B). As well, there was no change in body weight of mice
treated with silvestrol (Fig. S7) or any signs of illness or distress.
Additionally, there was no appreciable change in liver or spleen
weight (Fig. 4C). In vivo toxicity can be monitored by the
appearance of enzymes in the serum such as ALT and AST.
However, rather than an elevation of ALT or AST levels as
expected for liver or muscle damage, we observed a slight
reduction in AST levels and a 50% decrease in ALT levels, likely
reflecting the inhibition of protein synthesis exerted in vivo by
silvestrol (Fig. 4C). Collectively, these data indicate that silvestrol
appears well tolerated in normal tissues.
Silvestrol suppresses HUVEC cell growth
The potential consequences of silvestrol on angiogenesis have
not been explored, so we evaluated if it could suppress the
response of endothelial cells to angiogenic stimuli. Silvestrol
inhibited protein synthesis in HUVEC cells (Figs. 5A, B) and did
not induce apoptosis even when cells were exposed to compound
for 72 h (Fig. 5B). We also evaluated the ability of silvestrol to
prevent or delay formation of tube or chord-like structures by
HUVECs. Though this in vitro model does not fully recapitulate
the features of in vivo angiogenesis, it is none-the-less useful for
evaluating the response of endothelial cells to angiogenic stimuli.
Silvestrol prevented the ability of HUVECs cultured on Matrigel
to form vessel-like structures (Fig. 5C). This was quantitated by
Figure 4. Long-term administration of silvestrol is well tolerated. A. Silvestrol causes a transient depression of protein synthesis in liver of
mice receiving compound. Analysis of liver polysomes from mice injected two consecutive days with 0.2 mg/kg silvestrol and taken 3 or 6 h after the
last injection. B. Following 8 consecutive daily administrations of silvestrol (0.2 mg/kg) into Balb/c male mice, bone marrow (BM) and spleen (SP) cell
populations were quantitated by FACs analysis. The relative percentage (%) of each population is shown. C. Silvestrol does not alter spleen or liver
weights or increase liver aminotransferase activity. Eight Balb/c mice were administered daily injections of vehicle or silvestrol for 8 days. Alanine
(ALT) and aspartate (AST) aminotransferase levels, and spleen and liver weights were determined one day after the last injection. The bar represents
the mean of the measurements set relative to levels obtained from control mice for each cohort.
doi:10.1371/journal.pone.0005223.g004
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silvestrol caused a dose-dependent reduction in tube formation
(Fig. 5D).
Silvestrol suppresses xenograft tumor growth
Deregulated eIF4F activity has been postulated to contribute to
the oncogenic process in breast cancers [28]. We therefore chose
to evaluate the impact of silvestrol administration on tumor growth
in MDA-MB-231 breast cancer xenografts (Fig. 6). At 11 days
after implantation, silvestrol was administered intraperitonally at
0.5 mg/kg once per day for 8 consecutive days. Following
treatment, mice were monitored for up to 2 months and we
noted that silvestrol dramatically suppressed the growth of these
tumors (Fig. 6A and B). In these experiments, we used two
different passages of MDA-MB-231 cells, an early passage that
appeared to be slower growing in vivo (Fig. 6A) and a late passage,
faster growing, line (Fig. 6B). In contrast to silvestrol treatment,
administration of doxorubicin or rapamycin did not inhibit tumor
growth (Fig. 6B). However, synergy with doxorubicin was
observed for both rapamycin and silvestrol in vitro when tested
against MDA-MB-231 cells (Table 1). An additional xenograft
model that we used was the PC-3 human prostate cancer model,
since the AKT/mTOR signaling pathway is frequently upregu-
lated in these cancers [29,30]. Growth of PC-3 xenografts was also
significantly reduced in mice dosed with 0.5 mg/kg silvestrol for 8
consecutive injections following appearance of the tumors 24 days
after implantation (Fig. S8). This observation contrasts with the
results obtained with Dox at 5 mg/kg, which showed little effect.
Figure 5. Silvestrol inhibits protein synthesis and suppresses endothelial cell tube formation. A. The relative rate of
35S-Met
incorporation in HUVECs as a function of silvestrol concentration. Cells were exposed to the indicated concentrations of silvestrol for 1 h, and in the
last 15 min,
35S-Met was added to the cells. Extracts were prepared and the amount of TCA-insoluble
35S-Met determined. Results are the average of
duplicates with the error of the mean too small to be seen. Values are standardized against total protein content. B. Kinetics of protein inhibition
versus cell death following exposure of HUVECs to silvestrol. HUVECs were exposed to 25 nM silvestrol for the indicated periods of time. One hour
before the end of treatment, media was removed, cells washed with PBS and incubated for an additional hour with silvestrol in Met-free DMEM. For
the last 15 min, cells were labeled with
35S-Met, followed by TCA precipitation and scintillation counting. A parallel set of dishes (200,000 cells/well in
a 6-well plate) were used to measure the percentage of viable cells by Annexin V/P.I. staining and FACs analysis. These values were normalized to
those obtained in the presence of 1% DMSO, which was set at 100%. These values are plotted on the right ordinate and as a dashed line. C.
Disruption of tube formation by HUVECs in the presence of silvestrol. HUVECs were seeded on BD Matrigel
TM Matrix basement membrane (BD
Biosciences, Bedford MA) in 24-well plates in triplicate in the presence of increasing concentrations of silvestrol and 24 h later monitored for tube
formation. Photographs were taken with a Nikon eclipse TE300 microscope. The bar at the bottom of each photograph corresponds to 50 mm D.
Quantitation of tubules (chord-like structures) observed per field. A total of 15 different fields were used for each data point and the errors represent
the standard deviation.
doi:10.1371/journal.pone.0005223.g005
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analyzed to determine the fraction of apoptotic and dividing cells
(Fig. 6C). TUNEL staining showed a significant increase in
silvestrol-treated tumor cells staining positive for apoptosis and
proliferation of silvestrol-treated tumor cells was greatly reduced as
judged by staining for Ki67 (Fig. 6C).
Discussion
Deregulated translation initiation through elevated eIF4E levels
and increased eIF4F activity has been repeatedly implicated in
malignancy through the altered translation of pro-survival and
pro-growth encoding mRNAs that contribute to oncogenesis
[31,32], angiogenesis [17], and chemoresistance [33]. Recently,
integrated genomic analysis of human glioblastoma multiforme,
pancreatic cancers, breast and colon cancers revealed that human
cancers contain a large number of genetic alterations (e.g. an
average of 63 genetic alterations for pancreatic cancers) that define
a core set of cellular signaling pathways and processes that are
altered in a large number of tumors (67–100% in pancreatic
cancers) [34]. In the case of pancreatic cancers, these include K-
ras signaling, invasion, Small GTPase-signaling, apoptosis, inte-
grin signaling, DNA damage control, notch signaling, and JNK
signaling – all pathways that converge on eIF4E [35–41]. Hence
inhibiting the eIF4F checkpoint suppresses tumor growth through
multiple mechanisms and provides a rationale for development of
broad-acting therapeutics. We show here that targeting the eIF4A
Figure 6. Silvestrol suppresses xenograft tumor growth. A. Response of nude mice bearing early passage human MDA-MB-231 breast cancer
to silvestrol. Dosing schedule is indicated at the start of Day 11. Small crosses indicate loss of 2 animals during the course of the experiment. B.
Response of nude mice bearing late passage human MDA-MB-231 breast cancer to silvestrol, doxorubicin, or rapamycin. Dosing schedule is indicated
at the start of Day 11. C. Xenografts were evaluated by TUNEL and immunohistochemistry for Ki67. Representative data are shown for control-treated
and silvestrol-treated mice.
doi:10.1371/journal.pone.0005223.g006
Table 1. Synergy of Doxorubicin with rapamycin and
silvestrol on MDA-MB-231 cells.
Combination Ratio CI(ED50) CI(ED75) CI(ED90) Average CI
Dox+Rap 1.47:1 1.159 0.789 0.538 0.83
Dox+Silv (Exp #1) 2.94:1 0.712 0.295 0.123 0.38
Dox+Silv (Exp #2) 11.79:1 0.414 0.270 0.183 0.29
Dox+Silv (Exp #3) 0.18:1 0.483 0.215 0.096 0.27
doi:10.1371/journal.pone.0005223.t001
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reduce tumor cell proliferation.
Silvestrol was the most active cyclopenta[b]benzofurans inhib-
iting protein synthesis among those that we tested. Interestingly,
this compound has the same core structure as compound #2,
which did not inhibit cap-dependent protein synthesis to the same
extent as other compounds tested - notably #6, 7 and 8. The
acetate moiety on compound #7 seems to be an important
contributor to increasing this compound’s activity relative to
compound #2. These results indicate that silvestrol’s activity may
be improved by incorporating this functional group. Clearly, the
dioxane moiety of silvestrol is a major contributor to its activity.
Cyclopent[bc]benzopyrans and benzo[b]oxepines did not show
any inhibition of protein synthesis (Fig. S2) indicating that the core
benzofuran ring system is essential for this property. Cyclo-
pent[bc]benzopyrans and benzo[b]oxepines have shown no
antiproliferative activity for cancer cell lines in vitro, consistent
with the idea that inhibition of protein synthesis by cyclopenta[b]-
benzofurans is responsible for their anti-proliferative activity [42].
In the current study, we also provide mechanistic insight into
the mode of action of silvestrol. We confirm that RNA binding of
eIF4Af is increased in the presence of silvestrol using an RNA filter
binding assay and that this binding is inhibited by hippuristanol
(Fig. 2A). The increased crosslinking of eIF4Ac to mRNA from
RSW was shown to be cap-dependent (Fig. 2B). There are several
possibilities to explain these results including stabilization of
eIF4Ac in the eIF4F complex by silvestrol, increased recycling of
eIF4Af through the eIF4F complex during initiation, or altered
conformation of eIF4Ac induced by silvestrol that favors cross-
linking (e.g.-exposure of an amide residue). We find less eIF4Ac
associated with the eIF4F complex when eIF4F is isolated by
m
7GTP-Sepharose affinity column from RSW or silvestrol-treated
cells (Fig. 2C), consistent with the idea that silvestrol depletes the
eIF4F complex of eIF4A. We find no increase in eIF4G associated
with RNA-bound eIF4A indicating that the eIF4F complex is not
sequestered to RNA by silvestrol (Fig. 2D).
We have previously reported that administration of silvestrol to
mice bearing Em-myc derived lymphomas synergizes with standard-
of-care agents, such as doxorubicin, to induce apoptosis in vivo [4].
However, as a single agent silvestrol was not effective at curtailing
lymphoma development in this model [4]. In the current setting,
silvestrol was effective as a single agent against two different human
xenograft models, resulting in tumor growth arrest associated with
massive apoptosis and halt of cellular proliferation (Fig. 6). The
reasons for these differences are not immediately apparent, but may
be related to the presence of an activated c-myc allele in the Em-myc
model.Alternatively,silvestrol’santi-angiogeniceffects(Fig.5)maybe
quite important for its anti-proliferative activity against solid tumors,
but less so towards lymphomas. Alternatively, it may be that the
tumors used in the current study are more ‘‘addicted’’ to altered
translation initiation rates (due to increased numbers of altered
signaling pathways or processes) than the Em-myc/PTEN tumors
previously used [4], and hence respond to single agent treatment.
Interestingly, rapamycin showed no effect in the MDA-MB-231
xenograft model used here demonstrating the superiority of silvestrol
in the two models tested (Fig. 6B). Al t h o u g hh i g hc o n c e n t r a t i o n so f
doxorubicin (10 mg/kg) were sufficient to achieve an anti-tumor
response, the mice lost weight and did not thrive (R.C., data not
shown). A single dose of doxorubicin at 5 mg/kg was not effective
against MDA-MB-231 breast cancer cells in vivo, although rapamycin
and silvestrol did show synergy with doxorubicin in vitro (Table 1).
Many key proteins involved in malignancy are translationally
controlled, including the potent angiogenic factors VEGF and
FGF-2, the oncogenes cyclin D1 and c-myc, the antiapoptotic
proteins of the Bcl family, as well as the inhibitor of apoptosis
protein survivin (refs. 30, 31; see ref. 1 for a more extensive list of
translationally controlled proteins involved in malignancy).
Indeed, modulation of eIF4E can directly affect the expression
of many of these malignancy related proteins (reviewed in refs. 1,
30). One prediction is that silvestrol should preferentially inhibit
the translation of mRNAs whose expression is more dependent on
eIF4F for ribosome recruitment. Indeed, silvestrol (and Com-
pound #7) showed a preference for affecting the translation of
‘‘weaker’’ mRNAs (Figs. 3C, S3B, S4 and S5). This discriminatory
effect is consistent with silvestrol targeting the eIF4F complex and
inhibiting ribosome recruitment. Our results do not exclude an
additional effect of silvestrol on protein stability. The ability of
silvestrol to induce formation of stress granules (Fig. S6) is expected
for an inhibitor of translation initiation.
The inhibition of protein synthesis that we observed with
silvestrol for MDA-MB-231 and PC-3 cells is very different than
that noted with 4E-antisense oligonucleotides. We observed a
biphasic response with a precipitous drop occurring over the first
8 h, followed by a slower reduction in translation occurring from
8–72 h (Fig. 3B). This result is in contrast to what has been
reported for eIF4E antisense oligonucleotides, where no reduction
in global protein synthesis was observed over the course of 72 h
[17]. These differences may reflect the different requirements of
translation initiation for eIF4A versus eIF4E, since ribosome
recruitment to mRNAs containing unstructured 59UTRs can be
mediated by eIF4G/eIF4A in the absence of eIF4E [24].
Nonetheless, it does seem that inhibition of translation with
silvestrol can result in mRNA discriminatory effects (Fig. S4).
Administration of silvestrol appeared well tolerated in non-
tumor bearing mice without inducing appreciable toxicity (Fig. 4
and Fig. S7). In normal resting cells translation initiation may be
very low as a large fraction of eIF4E may be complexed with the
inhibitory 4E-BPs in the absence of Akt/mTOR pathway
stimulation [28]. As well, in normal cells stimulated to proliferate,
the spectrum of mRNA whose translation is elevated may differ
significantly from those elevated in transformed cells. Consistent
with this hypothesis, increased phosphorylation of 4E-BP (pre-
sumably leading to elevated eIF4F activity) in liver from mice
administered the branched chain amino acid (which activates
mTOR) stimulates ribosomal protein mRNA translation but not
global rates of protein synthesis in liver [43]. Yet, altering eIF4E
levels by transcriptional activation [44], knock down using
shRNAs [44], or inhibiting mTOR activity [45] in transformed
cells can affect mRNA-selective translation and global rates of
protein synthesis (,2-fold decrease). The alteration in global
translation rates may be due to a larger pool of mRNAs that are
discriminated by eIF4E in tumor cells. Using anti-sense oligonu-
cleotides to knockdown expression of eIF4E in the mouse is also
well tolerated [17]. Our results support the idea that curtailing
translation initiation by modulating eIF4A activity is a promising
anti-cancer therapeutic approach that is well tolerated.
Materials and Methods
Ethics Statement
All animal studies were approved by the McGill University
Faculty of Medicine Animal Care Committee
General Reagents
Silvestrol was resuspended in DMSO and stored at 270uC.
Doxorubicin (Sigma) was dissolved in water and stored at 4uC.
Rapamycin (LC Laboratories, Woburn, MA) was resuspended in
100% ethanol and stored at 270uC.
eIF4A as Anti-Cancer Target
PLoS ONE | www.plosone.org 9 April 2009 | Volume 4 | Issue 4 | e5223Cell culture
Malignant metastatic human mammary epithelial MDA-MB-
231 cells were obtained from the American Type Culture
Collection (ATCC, Rockville, MD) and grown as monolayers in
L15 medium (Invitrogen) supplemented with 10% fetal bovine
serum and 100 U/ml penicillin/streptomycin. PC-3 cells were
obtained from the American Type Culture Collection (ATCC,
Rockville, MD) and grown as monolayers in F12-K medium
(Invitrogen) supplemented with 10% fetal bovine serum and
100 U/ml penicillin/streptomycin. HUVEC cells were obtained
from Lonza (Walkersville, MD) and propagated in EBM-2
medium supplemented with EGM-2.
Recombinant DNA constructs and in vitro translations
The bicistronic reporter, FF/HCV/Ren, has been previously
described [46]. For generating reporter constructs containing a G-
quadruplex or a [CAA] tract for in vitro translation assays, the plasmid
phRL-null was used (Promega). This plasmid was linearized with
NheI/NcoI and gel purified. Two sets of annealed oligonucleotides
were inserted into these sites. One set [sense:
59CTAG[CAA]10C
39
and antisense:
59CATGG[TTG]10
39 ] generated [CAA]10/RL,
whereas Set II [sense:
59CTAGGGGAGGGGCGGGTCTGGG[-
CAA]4C
39 and antisense:
59CATG[GTT]4CCCAGACCCGC-
CCCTCCC
39] generated G-Q(+6)/RL. Plasmid G-Q(+6)/RL
contains the G quadruplex from NRAS positioned six nucleotides
downstream from the T7 RNA polymerase transcription start site
[23]. Plasmids encoding CAT or PLTARCAT have been previously
described [47].
For in vitro translations, constructs G-Q (+6)/RL and [CAA]10/
RL were linearized with XbaI followed by in vitro transciption with
T7 RNA polymerase. Plasmid pSP72/HCV/Luc A+ (a gift from
Dr. N. Sonenberg [McGill University]) was linearized with BamHI
and subsequently in vitro transcribed with T7 RNA polymerase. In
vitro translations where performed with 0.2 ng/ml in vitro
transcribed RNAs in micrococcal nuclease treated Krebs extract
as described previously [46] with the indicated concentrations of
silvestrol for 1 h at 30uC. FF and Ren luc activity (RLU) were
measured on a Berthold Lumat LB 9507 luminometer. In vitro
translations of FF-HCV-Ren in RRL (Promega) were performed
according to the manufacturer’s instructions.
Filter Binding and Crosslinking Assays
Filterbindingand chemicalcrosslinkingassayswere performed as
previously described [22,48]. For crosslinking assays, a 30 mL
reaction containing 10 mL ribosomal salt wash (RSW) (1.2 mg/mL)
was incubated under standard conditions (25 mM Hepes [pH 7.5],
70 mM GTP, 11 mM of each of the amino acids, 2 mM DTT,
60 mM PMSF and 0.5 mM Mg(OAc)2) with 0.9 mM ATP (unless
indicated otherwise) in the presence of oxidized
32P-labeled CAT
RNA (50,000 cpm). Reactions were incubated for 10 min at 30uC
and then crosslinked using 20 mM NaBH3CN overnight at 4uC.
After treatment with RNAse A, proteins were separated by 10%
SDS-PAGE and visualized by autoradiography (Kodak X-Omat).
35S-methionine labeling and Western blotting
Malignant metastatic human mammary epithelial MDA-MB-
231 cells were obtained from the American Type Culture
Collection (ATCC, Rockville, MD) and grown as monolayers in
L15 medium (Invitrogen) supplemented with 10% fetal bovine
serum and 100 U/ml penicillin/streptomycin. PC-3 cells were
obtained from the American Type Culture Collection (ATCC,
Rockville, MD) and grown as monolayers in F12-K medium
(Invitrogen) supplemented with 10% fetal bovine serum and
100 U/ml penicillin/streptomycin. HUVEC cells were obtained
from Lonza (Walkersville, MD) and propagated in EBM-2
medium supplemented with EGM-2.
To measure the rate of
35S-Met incorporation into protein,
60,000 cells/well were seeded in a 24-well plate. The following
day, the medium was removed, cells washed with PBS and
exposed to silvestrol at the indicated concentrations in methionine-
free DMEM supplemented with 10% dialyzed serum for 1 hr. For
the last 15 min, cells were labeled with
35S-methionine. Medium
was removed, cells washed in PBS and lyzed in RIPA buffer
(20 mM Tris [pH 7.5], 100 mM NaCl, 1 mM EDTA, 1 mM
EGTA, 0.1% NP-40, 0.5% sodium desoxycholate, 0.1% SDS,
20 mM ß-glycerophosphate, 10 mM NaF, 1 mM PMSF, 4 mg/ml
aprotinin, 2 mg/ml leupeptin, 2 mg/ml pepstatin) for 20 min with
shaking at 4uC. The protein was TCA precipitated and the
radioactivity quantitated by scintillation counting. Protein content
in the cell lysates was measured using the Bio-Rad DC
ProteinAssay (Bio-Rad Laboratories) and used to standardize the
counts obtained by TCA precipitation.
To visualize
35S-methionine labeled proteins, equal amounts of
extracts were resolved on 10% SDS-polyacrlamide gels, stained
with Coomassie Blue to verify equivalent loading, treated with
En
3Hance, dried and exposed to X-OMAT X-ray film (Kodak).
To monitor cellular viability, 200,000 cells/well were seeded in
a 6-well plate and treated with 25 nM silvestrol for the indicated
times. At the end of the treatment, the cell media was collected,
cells were washed with 1 ml PBS and trypsinized with 200 ml
trypsin. Cells were collected and pooled with the initial media and
PBS wash. Samples were spun at 4uC for 2 min at 2000 rpm in a
Sorval LegendRT table centrifuge. The pellet was resuspended in
2 ml cold PBS followed by another 2 min spin at 2000 rpm. The
pellet was resuspended in 100 ml Annexin V binding buffer
(10 mM HEPES [pH 7.4], 140 mM NaCl, 2.5 mM CaCl2)
followed by the addition of propidium iodide to a final
concentration of 5 mg/ml. After addition of 5 ml Annexin V-
FITC (BD- Biosciences), samples were incubated for 15 min at RT
in the dark followed by the addition of 400 ml of Annexin V
binding buffer. FACS analyses were performed using a FACScan
instrument from BD Biosciences and CELLQUEST software.
For Western blot analysis, cells were grown in 6-well plates,
washed with PBS, harvested with a rubber policeman, and collected
by brief centrifugation. Cell pellets were lyzed in RIPA buffer and
separated on a 10% SDS-polyacrylamide gel followed by transfer to
a PVDF membrane (Millipore). Primary Antibodies used were anti-
Cyclin D1 (Cell Signaling, Danvers, MA), anti-Bcl-2(Cell Signaling,
Danvers, MA), anti-c-myc (Santa Cruz, Santa Cruz, CA), anti-Mcl-
1 (Rockland, Gilbertsville, PA), anti-Survivin (Novus, Burlington,
ON), and anti-tubulin (Sigma-Aldrich, Oakville, ON) and anti-
GAPDH (Abcam, Cambridge, MA). Secondary antibodies were
from Jackson Immuno Research (Burlington, ON).
Monitoring Stress Granule Formation
Anti-eIF4A and anti-G3BP antibodies have been previously
described [49,50]. Anti-eIF4E antibody was a gift of S. Kimball and
has been described previously [51]. Cells were processed for
immunofluorescence as previously described [50]. Essentially, cells
were fixed in 3% paraformaldehyde and permeabilised with 0.1%
Triton-X100/PBS. Slides were incubated with primary antibodies
diluted in 0.1% normal goat serum for 1 h at RT. Following
washing, the slides were incubated with goat anti-mouse/rabbit IgG
(H+L) secondary antibodies coupled to goat Alexa Fluor 488/594.
Fluorescence microscopy was performed using a Zeiss Axiovision
3.1 microscope equipped with Axiocam HR (Zeiss) digital camera.
Images were compiled using Adobe Photoshop software.
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RSW was incubated in the presence of 0.5% of DMSO or
50 mM silvestrol for 1 h at 30uC, followed by the addition of
50 mL of 50% m
7GTP-Sepharose beads (G.E. Healthcare). The
reactions were incubated for 2 h end-over-end at 4uC, after which
the beads were washed three times with 240 mL of LCB (20 mM
HEPES [7.5], 100 mM KCl, 0.2 mM EDTA), and twice with
240 mL of LCB+ 200 mM GDP. Proteins were eluted with 120 ml
of LCB+ 200 mMm
7GTP for 10 min on ice.
For eIF4F pulldown experiments from cell extracts, 8610
6
MDA-MB-231 cells were seeded into 15 cm
2 dishes and the next
day treated with 25 nM silvestrol for 4 h. Cells were washed in
cold PBS, scraped with a rubber policeman and spun down for
5 min at 2500 rpm. Cell pellets were resuspended in lysis buffer
(20 mM Tris [7.5], 100 mM KCl, 1 mM DTT, 1 mM EDTA,
0.2% Tween20, 20 mM ß-glycerophosphate, 10 mM NaF, 1 mM
PMSF, 4 mg/ml aprotinin, 2 mg/ml leupeptin, 2 mg/ml pepstatin)
and immediately put on dry ice. Following 3 freeze-thaw cycles,
extracts were centrifuged for 10 min at 14,0006g to remove cell
debris. Pulldowns were performed with 1 mg of total protein
extract and 50 ml of 50% m
7GTP-Sepharose beads (GE
Healthcare) for 2 h end-over-end at 4uC. Beads were washed 3
times with lysis buffer, once with LCB+ 500 mM GDP and
proteins eluted with LCB+ 500 mMm
7GTP for 10 min on ice.
m
7GTP elutions were analyzed on a 10% polyacrylamide gel,
followed by transfer to a PVDF membrane.
For poly (rG) pulldown experiments, 500 mL of Krebs-2 extract
was incubated with 0.5% DMSO, 10 mM pateamine or 50 mM
silvestrol for 10 min at 4uC, followed by the addition of 50 mlo f
50% Poly(rG) agarose (Sigma). Pulldowns were incubated for 1 h
at 4uC. After incubation, the beads were washed twice with 10
volumes wash buffer (20 mM HEPES [7.5], 250 mM KOAc,
0.1% NP-40, 1 mM DTT). SDS elutions were resolved on a 10%
SDS-polyacrylamide gel and transferred to PDVF membranes
(Millipore). Antibodies used were anti-eIF4A [10] and anti-eIF4GI
(Bethyl, Montgomery, TX), respectively. Secondary antibodies
were from Jackson Immuno Research (Burlington, ON).
Drug Synergy Assessment
MDA-MB-231 cells were seeded at 10,000 cells/well in a 96-
well plate. The cells were allowed to adhere to the bottom of the
plates for 24 h in complete media and then exposed to drug or
vehicle in fresh media for the indicated periods of time. At the end
of treatment, cells were washed with PBS followed by addition of
200 ml PBS to each well. Cell proliferation was monitored using
the sulforhodamine B (SRB) assay [52]. Drug interaction was
assessed by the combination index method of Chou and Talalay
using CalcuSyn software (BioSoft, Cambridge, UK) [53].
Animal Studies
For xenograft models, 5610
6 MDA-MB-231 or PC-3 cells were
injected with matrigel sub-cutaneously into the right flank of 4–6
weeks old female Balb/c nu/nu mice. Tumor growth was
monitored every day using calipers. Treatments were started
when tumors had reached 25–50 mm
3. Nude mice bearing tumors
were dosed I.P. with vehicle (5.2% PEG400/5.2% Tween80),
silvestrol (0.5 mg/kg), doxorubicin (5 mg/kg), or rapamycin
(4 mg/kg). Tumor growth was then monitored for the remainder
of the experiment and no further injections were made. For
fixation, tumors were fixed in 10% formalin and embedded in
paraffin for further analysis. TUNEL staining was performed using
the In Situ Cell Death Detection Kit, POD (Roche) following the
manufacturer’s protocol. For Ki67 staining, the rabbit monoclonal
Ki67 (Clone SP6) antibody was purchased from Thermo
Scientific. Antigen retrieval was performed by boiling samples
for 15 min in 10 mM Citrate buffer [pH 6.5]. Sections were
incubated with primary antibody for 1 h at RT. The Ultravision
Detection System Anti Rabbit, HRP,DAB (Thermo Scientific) was
used according to the manufacturer’s instructions.
Toassesscytotoxicityofsilvestrol,sixmalewtBalb/cmice,8weeks
old, were treated with vehicle (5.2% PEG 400/5.2% Tween-80) or
0.2 mg/kg silvestrol for 8 consecutive days. Fresh cell suspensions of
bone marrow (BM) and spleen (SP) were prepared in PBS+ 2% FBS.
Nonspecific binding was blocked by incubation of the samples with
purified anti-CD16/CD32 antibody (clone: 2.4G2; BD Biosciences)
for 5 mins on ice before labeling of the cells with a combination of
fluorochrome conjugated substrate specific antibodies. Antibodies
used to identify monocytes and granulocytes were: Ly-6G/Ly-6C
(Gr-1) PECy7 (clone RB6-8C5; Biolegend) and CD11b PE (clone
M1/70; BD Biosciences). Antibodies used to identify T and B
lymphocytes were: CD4 FITC (clone RM4-5; BD Biosciences), CD8
CyChrome (clone 53-6.7; BD Biosciences) and CD45R/B220 APC
(clone RA3-6B2; BD Biosciences). Red blood cells were identified
with the antibody Ter119 Biotin (clone ter119; Biolegend) followed
by a streptavidin Pacific blue conjugated antibody (Invitrogen/
Molecular Probes). Incubation was performed in the dark on ice for
30 min before data acquistion and analysis was conducted on a
FACSAria machine (BD Biosciences) by using CELLQUEST (BD
Biosciences) or FlowJo (Treestar) softwares.
Polysome profiling analysis on liver extracts was performed on
male wt Balb/c mice, 6–8 weeks old. Mice were injected with
vehicle (5.2% PEG 400/5.2% Tween-80) or 0.2 mg/kg silvestrol
for 2 days. Three and six hours after the second injection, animals
were sacrificed, and the livers excised and washed in cold PBS
containing 100 mg/ml cycloheximide. The dissected livers were
homogenized in a Eurostar Power-b homogenizer (IKA Liver
Labortechnik, Staufen, Germany) in 3 volumes of lysis buffer
(40 mM HEPES [7.5], 100 mM KCl, 5 mM MgCl2, 100 mg/ml
cycloheximide). Homogenates were then centrifuged for 10 min at
1,2006ga t4 uC. The supernatant was transferred into a new tube
and to 150 ml of extract, 300 ml of lysis buffer containing 0.5%
Triton X-100 and 0.5% sodium deoxycholate were added and the
sample centrifuged briefly. Samples were loaded on 10–50%
sucrose gradients and centrifuged in an SW40 rotor at 35,000 rpm
for 2 h. Gradients were analyzed by piercing the bottom of the
tubes with a Brandel tube piercer and passing 60% sucrose
through the bottom. Recording of the data was performed using
InstaCal Version 5.70 and TracerDaq Version 1.9.0.0 (Measure-
ment Computing Corporation, Norton, MA).
NOTE ADDED IN PROOF
While this manuscript was under review, Lucas et al. (Lucas,
DM, Edwards, RB, Lozanski, G, et al. The novel plant-derived
agent silvestrol has B-cell selective activity in chronic lymphocytic
leukemia and acute lymphoblastic leukemia in vitro and in vivo.
Blood, 2009; [Epub ahead of print]) also showed reduction of Mcl-
1 protein following silvestrol treatment of acute lymphoblastic and
chronic lymphocytic leukemias.
Supporting Information
Figure S1 Relative potency of cyclopenta b benzofurans on cap-
and HCV-mediated translation initiation. A. Schematic diagram
of FF/HCV/Ren mRNA reporter used to program in vitro
translation extracts. B. Krebs-2 translation extracts were pro-
grammed with FF/HCV/Ren mRNA and vehicle (MeOH) or
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translations performed in the presence of [
35S]-methionine is
shown. Following separation of protein products on 10% SDS-
polyacrylamide gels, the gels were treated with EN
3Hance, dried,
and subjected to autoradiography. The position of migration of FF
and Ren luciferase proteins is indicated to the right.
Found at: doi:10.1371/journal.pone.0005223.s001 (1.55 MB EPS)
Figure S2 Translation properties of cyclopenta bc benzopyrans
and benzo b oxepines. A. Chemical structure of cyclopenta bc
benzopyrans and benzo b oxepines tested in this study. B. Effect of
compounds on cap- and HCV-mediated translation initiation.
Krebs-2 translation extracts were programmed with FF/HCV/
Ren mRNA and vehicle (MeOH) or 50 mM compound added. A
representative autoradiograph of an in vitro translation reaction
performed in Krebs-2 extracts with [
35S]-methionine is shown.
Following separation of protein products by SDS-PAGE, the gels
were treated with EN
3Hance, dried, and subjected to autoradi-
ography. The position of migration of FF and Ren luciferase
proteins is indicated to the right.
Found at: doi:10.1371/journal.pone.0005223.s002 (6.70 MB EPS)
Figure S3 Effect of silvestrol exposure on global protein synthesis
in MDA-MB-231 and PC-3 cells. A. Cells were exposed to 25 nM
silvestrol for the indicated time points and radiolabeled with
35S-
Met for the last 15 min of incubation. Cell extracts were prepared
and equivalent protein amounts were loaded on 10% SDS-
polyacrylamide gels. After electrophoresis, gels were stained with
Coomassie blue to verify equal loading, treated with En
3Hance,
dried, and exposed to X-OMAT X-ray film (Kodak). Open squares
identified some proteins whose abundance was reduced after 24 h.
B. Six million cells (MDA-MB-231) were seeded in 15 cm
2 dishes
24 h before treatment with 25 nM silvestrol or vehicle (DMSO) for
1 h. Cells were harvested by scraping with a rubber policeman in
cold PBS containing 100 mg/ml cycloheximide and centrifuged for
10 min at 20006ga t4 uC. Pellets were resuspended in 425 ml
hypotonic lysis buffer (5 mM Tris 7.5, 2.5 mM MgCl2, 1.5 mM
KCl) followed by addition of 5 ml1 0mg/ml cycloheximide, 1 mM
DTT, 0.5% Triton X-100 and 0.5% sodiumdeoxycholate. Samples
were loaded on 10–50% sucrose gradients and centrifuged in an
SW40 rotor at 35,000 rpm for 2 h. Gradients were analyzed by
piercing the bottom of the tubes with a Brandel tube piercer and
passing 60% sucrose through the bottom. Fractions were collected
from the gradients and monitored with an ISCO UA-6 UV detector
(left panel). Fractions were separated into unbound and polysome
(Poly)-bound regions. RNA was isolated using Trizol according to
the manufacturer’s instructions (Invitrogen). One-twentieth of the
pooled RNA fractions was reverse transcribed using SuperScript
TM
II (Invitrogen) primed with oligo(dT)12–18. PCRs were performed
with undiluted, 1:10 or 1:100 diluted cDNA samples. Primers used
werehCyclinD1 [59 CTCCTCTCCGGAGCATTTTGAT 39 and
59 CACCGCTCAGGGTTATGCAAAT 39], hBcl-2 [59 TGAT-
GGGATCGTTGCC 39 and 59 CGCGGAACACTTGATT 39],
hSurvivin [59 GGCCCAGTGTTTCTTCTGCTT 39 and 59 TT-
GACAGAAAGGAAAGCGCAAC 39], hMcl-1 [59 TTCAGC-
GACGGCGTAACAAACT 39 and 59 CCCATCCCAGCCTCT-
TTGTTTA 39], and hc-Myc [59 AAGAAATTCGAGCTG-
CTGCCCA 39 and 59 AACTCTGGTTCACCATGTCTCC 39].
Annealing temperatures for hBcl-2, hSurvivin and hMcl-1 were
55uC and annealing temperatures for hCyclin D1 and hc-Myc were
59uC and 63uC, respectively. PCRs were optimized to detect the
exponential phase of amplification and analyzed on 1.5% agarose
gels (right panel).
Found at: doi:10.1371/journal.pone.0005223.s003 (10.21 MB
EPS)
Figure S4 Silvestrol inhibition of translation leads to mRNA
discrimination. A. Schematic diagram of constructs used in this
study. The renilla and firefly luciferase ORFs are represented by
grey and blackened boxes, respectively. B. In vitro translation of
mRNAs performed in Krebs extracts programmed with 0.2 mg/ml
HCV/FF and 0.2 mg/ml of either [CAA]10/RL or G-Q(+6)/RL
mRNA. The concentrations of hippuristanol, m
7GDP, or GDP
present in the reactions are indicated. Luciferase values were read
on a Berthold Lumat LB 9507 luminometer. Renilla luciferase
values were normalized to the firefly luciferase values and
calculated relative to the vehicle control (set at 1). The values
represent the average of 2-4 reactions with the error of the mean
shown. Renilla luciferase values from the vehicle control were
,20,000 and 150,000 RLU for translations programmed with G-
Q(+6)/RL and [CAA]10/RL, respectively. Firefly luciferase values
for vehicle-containing translations programmed with HCV/FF
were ,250,000 RLU. C. In vitro translation of mRNAs in the
presence of increasing concentrations of silvestrol. Translations
were performed in Krebs extracts programmed with 0.2 mg/ml
HCV/FF and 0.2 mg/ml of either [CAA]10/RL or G-Q(+6)/RL
mRNA. The concentrations of silvestrol present in the translation
reactions are indicated. Luciferase values were read on a Berthold
Lumat LB 9507 luminometer. Renilla luciferase values were
normalized to the firefly luciferase values and calculated relative to
the vehicle control (which was set at 1). The values represent the
average of 2–4 reactions, with the error of the mean shown. The
average firefly [HCV/FF] and renilla [G-Q(+6)/RL] values
obtained with the vehicle controls were ,320,000 and ,16,000
RLU, respectively. Average values for renilla obtained from
translation of [CAA]10/RL mRNA were ,100,000 RLU.
Found at: doi:10.1371/journal.pone.0005223.s004 (1.44 MB EPS)
Figure S5 mRNA discrimination by flavaglines is neither
silvestrol- nor reporter- specific. A. Predicted secondary structure
of PLTAR. B. Translation products of the indicated mRNAs from
Krebs extracts containing KOAc concentrations of 75 mM (lanes
4 and 8), 100 mM (lanes 5 and 9), 125 mM (lanes 6 and 10), and
150 mM (lanes 7 and 11). The presence of vehicle (lanes 4–7) or
1 mM Compound 7 (lanes 8–11) is indicated. Fluorographs of the
dried gels are presented.
Found at: doi:10.1371/journal.pone.0005223.s005 (5.02 MB EPS)
Figure S6 Silvestrol induces the formation of SGs in HeLa cells.
A. Distribution of eIF4A in HeLa cells upon exposure to arsenite or
silvestrol. Cells were exposed to DMSO (0.5%) (top panel), arsenite
(0.5 mM for 1 h) (middle panel), or silvestrol (5 mM for 1 h) (bottom
panel), fixed and stained for eIF4A and G3BP. B. Distribution of
eIF4E in HeLa cells upon exposure to arsenite or silvestrol.
Found at: doi:10.1371/journal.pone.0005223.s006 (3.62 MB EPS)
Figure S7 Silvestrol does not cause weight loss over time. Eight
Balb/c mice were administered silvestrol (0.2 mg/kg) on a daily
basis for 8 days and their weights monitored at the indicated times.
Found at: doi:10.1371/journal.pone.0005223.s007 (0.65 MB EPS)
Figure S8 Silvestrol suppresses tumor growth in a PC-3 prostate
cancer xenograft model. Nude mice bearing human PC-3 prostate
cancer (,35 mm
3) were dosed I.P. with vehicle (5.2% PEG400/
5.2% Tween80), silvestrol (0.5 mg/kg), doxorubicin (5 mg/kg), or
rapamycin (4 mg/kg). Dosing schedule is indicated at the start of
Day 24.
Found at: doi:10.1371/journal.pone.0005223.s008 (1.06 MB EPS)
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